Enhanced tumour specificity of an anti-carcinoembrionic antigen Fab' fragment by poly(ethylene glycol) (PEG) modification.
Polyethylene glycol (PEG) modification of a chimeric Fab' fragment (F9) of A5B7 (alpha-CEA), using an improved coupling method, increases its specificity for subcutaneous LS174T tumours. PEGylation increased the area under the concentration-time curve (AUC0-144) in all tissues but there were significant differences (variance ratio test, F = 27.95, P < 0.001) between the proportional increases in AUC0-144, with the tumour showing the greatest increase. The increase in AUCtumour from F9 to PEG-F9 was similar to the reported increase from Fab' to F(ab')2 while the increase in AUCblood by PEGylation of F9 was only 21% of the reported increase from Fab' to whole IgG. A two sample t-test showed no significant differences between maximal tumour/tissue ratios for PEG-F9 and F9 while the tumour/tissue ratios for PEG-F9 remained high over a longer period, with tumour levels at least double those for F9. PEG-F9 emerges as a new generation antibody with potential advantages for both radioimmunotherapy and tumour imaging. Since there was a reduction in antigen binding, optimisation of PEGylation might further improve tumour specificity. The latter resulted from complex effects on both the entry into and exit rates from tumour and normal tissues in a tissue-specific fashion.
Molecular Cell Pathology Laboratory, Royal Free Hospital School of Medicine, London, UK.
C
C
Delgado
R B
RB
Pedley
A
A
Herraez
R
R
Boden
J A
JA
Boden
P A
PA
Keep
K A
KA
Chester
D
D
Fisher
R H
RH
Begent
G E
GE
Francis
D000230:Adenocarcinoma / Q000276:immunology / Q000378:metabolism; D000818:Animals; D000911:Antibodies, Monoclonal / Q000493:pharmacokinetics*; D000912:Antibodies, Neoplasm / Q000187:drug effects / Q000378:metabolism*; D000918:Antibody Specificity / Q000187:drug effects*; D001666:Binding Sites, Antibody; D001682:Biological Availability; D002272:Carcinoembryonic Antigen / Q000276:immunology*; D003110:Colonic Neoplasms / Q000276:immunology / Q000378:metabolism; D005260:Female; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000737:chemistry / Q000187:drug effects / Q000276:immunology / Q000378:metabolism*; D016014:Linear Models; D051379:Mice; D008819:Mice, Nude; D009368:Neoplasm Transplantation; D011092:Polyethylene Glycols / Q000737:chemistry*; D011993:Recombinant Fusion Proteins; D013450:Sulfones / Q000737:chemistry* / Q000494:pharmacology; D014018:Tissue Distribution
D000911:Antibodies, Monoclonal; D000912:Antibodies, Neoplasm; D002272:Carcinoembryonic Antigen; D007140:Immunoglobulin Fab Fragments; D011993:Recombinant Fusion Proteins; D013450:Sulfones; C069114:2,2,2-trifluoroethane sulfonyl-monomethoxypolyethylene glycol; C032605:2,2,2-trifluoroethanesulfonyl chloride; D011092:Polyethylene Glycols